- Home
- CEE vs INO Comparison
CEE vs INO Comparison
Compare CEE & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEE | INO |
|---|---|---|
| Founded | N/A | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.1M | 114.0M |
| IPO Year | 1994 | 1999 |
Fundamental Metrics
Financial Performance| Metric | CEE | INO |
|---|---|---|
| Price | $17.31 | $1.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 20.6K | ★ 722.1K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | N/A | $24,407.60 |
| Revenue Next Year | N/A | $331.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $11.20 | $1.30 |
| 52 Week High | $19.98 | $2.86 |
Technical Indicators
Market Signals| Indicator | CEE | INO |
|---|---|---|
| Relative Strength Index (RSI) | 38.23 | 44.98 |
| Support Level | $16.95 | $1.48 |
| Resistance Level | $18.35 | $1.78 |
| Average True Range (ATR) | 0.72 | 0.08 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 22.38 | 41.67 |
Price Performance
Historical ComparisonAbout CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.